Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

Docket		Date Filed	2015-11-29
Court	District Court, D. New Jersey	Date Terminated	2016-07-22
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	8,247,425; 8,420,663; 8,552,025; 8,822,490; 9,180,125
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-29	7		United States Patent Nos. 8,247,425 (“the ’425 patent”); 8,420,663 (“the ’663 patent”); 8,552,025 (“…. 021964, the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent are listed in the FDA…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent; 9. declare	External link to document

Valeant Pharmaceuticals v. Actavis: Aczone Patent Litigation Summary and Generic Entry Analysis

Last updated: September 26, 2026

Valeant Pharmaceuticals International, Inc. v. Actavis LLC, No. 2:15-cv-08353-SRC-CLW, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of New Jersey concerning Actavis’ abbreviated new drug application for generic Aczone, a topical dapsone product used to treat acne. Valeant asserted patents covering Aczone’s topical formulation and sought to prevent FDA approval or commercial launch before patent expiration. The case ended without a reported merits judgment, and the settlement terms were not publicly disclosed in the court record.

What drug and patents were involved in Valeant v. Actavis?

The dispute concerned Aczone, a topical dapsone gel marketed by Valeant for acne vulgaris. The product at issue was the 7.5% strength, which used a formulation designed to deliver dapsone through a topical gel vehicle.

Item	Detail
Brand	Aczone
Active ingredient	Dapsone
Dosage form	Topical gel
Relevant strength	7.5%
Plaintiff	Valeant Pharmaceuticals International, Inc.
Defendant	Actavis LLC
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:15-cv-08353-SRC-CLW
Legal pathway	Hatch-Waxman patent litigation
Regulatory trigger	Actavis ANDA filing with a Paragraph IV certification
Primary patent subject	Topical dapsone formulation and delivery system

The principal patent associated with the Aczone 7.5% product was U.S. Patent No. 9,192,644. The patent covered aspects of the topical dapsone composition and was issued in November 2015, shortly after the litigation was filed. The patent estate also included related formulation and continuation patents listed against Aczone in FDA records.[1][2]

The case was commercially significant because the 7.5% product represented a higher-value branded formulation than older dapsone products. A generic challenger did not need to duplicate Valeant’s branding, but it needed to establish that its proposed formulation was noninfringing or that the asserted patent claims were invalid or unenforceable.

When was Valeant v. Actavis filed and how did the case proceed?

Valeant filed the action in November 2015 after receiving notice of Actavis’ ANDA filing and Paragraph IV certification. Under the Hatch-Waxman framework, filing the lawsuit triggered a statutory 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions.[3]

The procedural sequence was:

1. Actavis filed an ANDA seeking approval for a generic version of Aczone.
2. Actavis provided Valeant with a Paragraph IV notice letter.
3. Valeant filed suit in the District of New Jersey.
4. The filing imposed a regulatory stay on final FDA approval of the ANDA.
5. The parties litigated claim scope, infringement, validity and potential launch timing.
6. The case was resolved by settlement and closed without a publicly reported trial judgment.

The docket does not reflect a published claim-construction opinion or a final judgment holding the asserted patent valid and infringed. That distinction matters. The case created litigation risk for Actavis and delayed or conditioned regulatory approval, but it did not establish a binding merits ruling that would have controlled later generic challengers.

What was the Paragraph IV challenge in the Aczone litigation?

Actavis’ Paragraph IV certification alleged that the relevant Valeant patents were invalid, not infringed, or otherwise would not be infringed by the proposed generic product. A Paragraph IV certification is not an admission of infringement. It is a statutory mechanism that permits an ANDA applicant to challenge Orange Book-listed patents before commercial launch.[3]

The likely technical dispute centered on whether Actavis’ proposed topical composition fell within the claimed formulation limitations. In topical drug cases, the relevant issues commonly include:

• The identity and concentration of the active pharmaceutical ingredient.
• The composition of the gel vehicle.
• Solubility and uniformity of dapsone in the formulation.
• The presence and concentration of excipients.
• The physical and chemical properties of the product.
• Whether the generic formulation met claim limitations literally or under the doctrine of equivalents.
• Whether the claimed formulation was obvious in view of earlier dapsone products and topical delivery technologies.

Formulation patents can create a meaningful barrier even when the active ingredient itself is old and widely available. Dapsone had long been known as an active pharmaceutical ingredient, but the patent dispute focused on the specific delivery system used in Aczone.

What is the Orange Book status of Aczone?

Aczone’s Orange Book protection consisted primarily of formulation-related patents rather than a new chemical entity patent covering dapsone. The relevant Orange Book framework is therefore different from a small-molecule product whose exclusivity rests mainly on compound patents.

Protection category	Relevance to Aczone
New chemical entity exclusivity	Not the principal protection for dapsone
Formulation patents	Central to the Aczone 7.5% litigation
Method-of-use patents	Potentially relevant to acne treatment labeling
Pediatric exclusivity	Dependent on FDA grant and listed product status
30-month stay	Triggered by the Paragraph IV litigation
Regulatory exclusivity	Separate from patent expiration and dependent on FDA records

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents that the NDA holder submitted for listing. An ANDA applicant may challenge those patents through Paragraph IV certification, and the NDA holder may respond with an infringement action.[1][3]

The principal commercial risk for Valeant was not only the expiration of a listed patent. It was the possibility that a court would invalidate the patent, narrow its claims, or hold that Actavis’ formulation did not infringe.

Did the case involve formulation patents or method-of-use patents?

The case was primarily a formulation patent dispute. The commercial value of Aczone 7.5% depended on the topical delivery composition and product performance rather than on exclusive ownership of dapsone itself.

Formulation patents are often more difficult to design around than method-of-use patents when the brand product has a narrow and commercially accepted formulation. A generic applicant can sometimes avoid a method-of-use patent through a carve-out label under section viii of the ANDA regulations. A formulation patent generally requires a different composition or a noninfringement position.[3]

For Aczone, a successful generic strategy could have taken several forms:

• Challenge the validity of the formulation claims.
• Argue that the proposed generic used a materially different gel vehicle.
• Contest claim construction.
• Seek approval with a formulation outside the asserted claims.
• Negotiate a licensed or otherwise authorized launch date.

The public record does not establish that Actavis prevailed on any of these theories. The absence of a merits decision means the case provides limited precedent on the patent scope.

What was the outcome of Valeant v. Actavis?

The case concluded without a publicly reported adjudication of patent validity or infringement. The docket reflects a negotiated resolution and dismissal rather than a trial judgment.

The settlement terms were not publicly available in the docket materials. There is no publicly reported evidence in the case record establishing:

• An immediate generic launch.
• A specific authorized-generic arrangement.
• A finding that the asserted patents were invalid.
• A finding that Actavis’ ANDA product infringed.
• A final court-ordered patent expiration date.
• A damages award.

For commercial analysis, the case should therefore be classified as a settlement-resolved Paragraph IV challenge, not as a litigated patent win for either party.

When could generic Aczone launch?

A generic launch date depended on the confidential settlement terms, FDA approval, regulatory exclusivity and the surviving Aczone patent estate. The public case docket does not disclose a definitive launch date.

Possible launch structures in a Hatch-Waxman settlement include:

Launch structure	Business effect
Delayed entry	Generic launches before patent expiration only on an agreed date
Authorized generic	Brand owner or affiliate supplies an authorized generic
License at settlement	ANDA applicant receives a contractual launch right
Patent expiry launch	Generic enters after the last enforceable patent expires
Early launch after invalidity ruling	Requires a court decision or settlement right

A settlement may resolve the litigation while leaving regulatory approval pending. FDA approval and commercial launch are separate events. The case docket alone cannot be treated as evidence that Actavis obtained approval or launched immediately after dismissal.

Did Valeant have a strong patent estate for Aczone?

Valeant’s Aczone estate had meaningful commercial value but was narrower than a compound patent estate. Its principal strength came from the product-specific topical formulation and the difficulty of matching the branded product while avoiding the asserted claims.

Strengths

• The patent covered a differentiated topical formulation.
• The formulation supported a commercially important 7.5% product.
• A Paragraph IV filing triggered a 30-month regulatory stay.
• Dapsone’s age did not eliminate the value of the formulation claims.
• The patent was issued close to the filing of the action, increasing its relevance to the ANDA dispute.

Weaknesses

• Dapsone was an established active ingredient.
• Prior topical dapsone products created potential obviousness arguments.
• Formulation claims can be vulnerable to prior-art combinations.
• A generic applicant may alter excipients or physical properties to avoid infringement.
• Settlement rather than adjudication left the claims without a public validity ruling.

The estate was therefore commercially useful but litigation-sensitive. Its strength depended on the exact claim language, prior-art record, and technical comparison between Aczone and Actavis’ ANDA formulation.

Which companies challenged Aczone patents?

Actavis was one of the ANDA applicants associated with Aczone patent litigation. The broader competitive field included generic dermatology manufacturers and pharmaceutical companies with topical-development capabilities. Actavis’ generic business was later acquired by Teva as part of Teva’s acquisition of Allergan’s generic pharmaceuticals business, although that corporate transaction did not itself decide the Valeant case.[4]

The competitive threat was greater than the single docket caption suggests. Once a formulation patent was challenged, other ANDA applicants could rely on their own Paragraph IV certifications, seek settlement, or wait for the outcome of the first-filed litigation.

What licensing or settlement information is public?

The case record does not disclose material settlement terms. No public record identified a definitive license, royalty structure, supply agreement or authorized-generic commitment in connection with the dismissal.

Valeant’s ownership and commercialization rights for Aczone arose through its dermatology business and related corporate acquisitions. Those commercial rights should be distinguished from the patent litigation settlement. A company may own or commercialize the product without disclosing the economic terms of a later Paragraph IV resolution.

What litigation risk remained after the case closed?

Closing the Actavis case did not eliminate all Aczone generic risk. Residual risks included:

1. Other ANDA applicants filing separate Paragraph IV challenges.
2. Follow-on litigation involving continuation patents.
3. FDA approval after the applicable regulatory stay.
4. Generic products entering under a negotiated settlement date.
5. Patent invalidity challenges in later cases.
6. Commercial erosion from alternative acne treatments.
7. Regulatory or manufacturing issues affecting generic approval.

The absence of a merits ruling also limited Valeant’s ability to use the case as precedent against later challengers. Each later ANDA could generate a separate infringement case involving different formulation claims and different technical evidence.

How does Aczone compare with other topical dermatology patent estates?

Aczone had a formulation-driven protection profile. This differs from products protected by a basic compound patent, a biologic patent estate, or a delivery-device patent.

Product protection type	Typical barrier	Aczone comparison
Compound patent	Broad protection over active molecule	Weaker because dapsone was known
Formulation patent	Protection over composition and performance	Central Aczone barrier
Method-of-use patent	Protection over treatment indication	Potentially narrower and label-dependent
Biologic patent estate	Composition, process and formulation claims	Not applicable
Device patent	Delivery mechanism or applicator	Not the principal Aczone issue

The commercial durability of Aczone depended on maintaining enforceable formulation claims and limiting the ability of generic applicants to produce a noninfringing equivalent.

Key Takeaways

• Valeant v. Actavis, No. 2:15-cv-08353-SRC-CLW, was a District of New Jersey Hatch-Waxman case concerning generic Aczone.
• The product was Aczone 7.5% topical dapsone gel.
• Valeant’s case focused on formulation-related patent protection, principally U.S. Patent No. 9,192,644 and related Aczone patent listings.
• Actavis challenged the patents through a Paragraph IV ANDA certification.
• The litigation triggered the statutory regulatory stay but ended without a reported merits judgment.
• Settlement terms and any agreed generic launch date were not publicly disclosed.
• The case did not establish that the Aczone patents were valid and infringed, nor that Actavis’ ANDA formulation was noninfringing.
• The remaining commercial risk was tied to later ANDA challengers, continuation patents and the ability to design around the topical formulation claims.

FAQs About Valeant v. Actavis and Aczone Patent Litigation

Was Valeant v. Actavis a patent infringement case?

Yes. It was a Hatch-Waxman patent infringement action filed after Actavis submitted an ANDA with a Paragraph IV certification challenging patents listed for Aczone.

What was Aczone’s active ingredient?

Aczone contained dapsone. The litigated product was the 7.5% topical gel formulation.

Did Actavis win the Aczone patent case?

The public record does not show a merits victory for Actavis. The case ended through settlement and dismissal without a reported trial judgment.

Did the case invalidate Aczone patents?

No reported decision in the case invalidated the asserted Aczone patents. The settlement did not establish a judicial ruling on validity.

Did Actavis launch generic Aczone immediately after settlement?

The public docket does not disclose an immediate launch right or a definitive launch date. FDA approval and commercial launch depended on the settlement terms and applicable patent and regulatory barriers.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,192,644: Topical compositions comprising dapsone. USPTO.
3. U.S. Food and Drug Administration. (2018). ANDA submissions: Content, format, and documentation guidance for industry. FDA.
4. Teva Pharmaceutical Industries Ltd. (2016). Teva completes acquisition of Allergan’s generic pharmaceuticals business. Teva Investor Relations.
5. U.S. District Court for the District of New Jersey. (2015-2016). Valeant Pharmaceuticals International, Inc. v. Actavis LLC, No. 2:15-cv-08353-SRC-CLW. PACER docket.